GlassScriptPhysician profile
Omar Khokhar
NPI 1386865244
$194,450.98
in general payments reported to CMS, 2019-2025
36 companies · $64K in 2025
The $64K reported for 2025 was more than what 98% of Gastroenterology (Internal Medicine) providers received nationally (typical 2025 total: $636).
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,810 · 2020: $3,030 · 2021: $11K · 2022: $15K · 2023: $16K · 2024: $81K · 2025: $64K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $137K · Travel and Lodging: $13K · Food and Beverage: $10K · Consulting Fee: $500 · Education: $48.33.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $137,059.50 |
| Travel and Lodging | $13,098.36 |
| Food and Beverage | $10,276.44 |
| Consulting Fee | $500.00 |
| Education | $48.33 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Aimmune Therapeutics, INC. | $87,921.37 | 2024-2025 | Zenpep, Vowst |
| Phathom Pharmaceuticals, INC. | $46,652.71 | 2024-2025 | Voquezna |
| Nestle Healthcare Nutrition INC. | $27,325.55 | 2021-2023 | |
| Abbvie INC. | $12,309.30 | 2019-2025 | |
| Allergan, INC. | $5,084.67 | 2019-2020 | |
| Genzyme Corporation | $3,862.20 | 2023-2025 | |
| Medtronic, INC. | $2,104.02 | 2023-2025 | Gi Genius |
| Janssen Biotech, INC. | $1,626.82 | 2019-2025 | Stelara, Simponi Aria, Simponi |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $1,532.52 | 2019-2025 | Xifaxan, Trulance |
| Takeda Pharmaceuticals U.S.A., INC. | $1,511.85 | 2019-2025 | Entyvio, Eohilia, Gattex |
| Pinnacle Biologics, INC | $941.62 | 2024 | Photofrin |
| Ardelyx, INC. | $814.92 | 2022-2025 | Ibsrela |
| Celgene Corporation | $447.90 | 2022-2024 | Zeposia |
| Madrigal Pharmaceuticals | $380.44 | 2024-2025 | Rezdiffra, Resmetirom |
| E.R. Squibb & Sons, L.L.C. | $373.06 | 2022-2024 |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intercept Pharmaceuticals, INC. | $340.80 | 2019-2023 | Ocaliva |
| Pfizer INC. | $166.96 | 2020-2025 | |
| Janssen Scientific Affairs, LLC | $159.26 | 2021-2023 | Stelara |
| Regeneron Healthcare Solutions, INC. | $123.93 | 2023-2025 | Dupixent |
| Ethicon US, LLC | $102.80 | 2019 | |
| Ferring Pharmaceuticals INC. | $88.68 | 2021-2022 | |
| Redhill Biopharma INC. | $82.20 | 2020 | |
| Janssen Pharmaceuticals, INC | $81.40 | 2019 | |
| Endogastric Solutions, INC | $73.40 | 2024 | Esophyx |
| Braintree Laboratories, INC. | $62.88 | 2019-2024 | Sutab, Suflave |
| Ironwood Pharmaceuticals, INC | $62.35 | 2020-2022 | |
| Fresenius Kabi USA, LLC | $43.14 | 2023 | Idacio |
| Qol Medical, LLC | $40.68 | 2021-2025 | Sucraid |
| Shionogi INC | $34.60 | 2019-2020 | |
| Concordia Pharmaceuticals INC. | $21.65 | 2019 | |
| Covidien LP | $20.13 | 2020 | |
| Lilly USA, LLC | $18.84 | 2024 | Omvoh |
| Shire North American Group INC | $14.75 | 2019 | |
| Echosens North America, INC. | $12.41 | 2025 | Fibroscan |
| Steris Corporation | $11.17 | 2020 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$100,000.00 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Omar Khokhar listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.